Mirum Pharmaceuticals Inc (MIRM)

$72.53 -0.42 (-0.58%)
Market Cap 3.66B
Revenue (ttm) 336.89M
Net Income (ttm) -87.94M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -26.10%
Debt to Equity Ratio 0.00
Volume 446,800
Avg Vol 773,516
Day's Range N/A - N/A
Shares Out 50.24M
Stochastic %K 34%
Beta 0.81
Analysts Strong Sell
Price Target $81.00

Company Profile

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercializat...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 667 4085
Address:
950 Tower Lane, Suite 1050, Foster City, United States
MomentumLurker
MomentumLurker Oct. 5 at 11:57 AM
$MIRM Healthcare technology growth. Testing resistance level. Volume expansion needed for continuation. Sector momentum.
0 · Reply
xbibackto65s
xbibackto65s Sep. 26 at 3:21 PM
$MIRM adding
1 · Reply
IN0V8
IN0V8 Sep. 24 at 2:26 PM
$MIRM Buy TD Cowen initiates coverage with buy rating; PT $95
0 · Reply
notreload_ai
notreload_ai Sep. 24 at 12:06 PM
TD Cowen started coverage of $MIRM with a Buy rating and a $95 price target. The company has three successful products for rare liver diseases and is developing volixibat (also known as SHP626) for pruritus.
0 · Reply
ZacksResearch
ZacksResearch Sep. 23 at 2:49 PM
$CRMD or $MIRM — Which biotech stock is the better bet? CorMedix’s DefenCath delivered $78.8M in 2025 H1 sales, propelling a full-year revenue guidance boost, while $MIRM’s Livmarli sales soared 79.1% YoY in H1 2025. Yet, CRMD’s Zacks Rank #1 (Strong Buy) and strategic Melinta acquisition give it a significant edge. Find out why CRMD is the stronger pick 👉 https://www.zacks.com/stock/news/2755750/crmd-vs-mirm-which-specialized-biotech-stock-is-the-better-pick?cid=sm-stocktwits-2-2755750-body-13685&ADID=SYND_STOCKTWITS_TWEET_2_2755750_BODY_13685
0 · Reply
ZacksResearch
ZacksResearch Sep. 23 at 1:49 PM
$CRMD vs. $MIRM — which biotech is the smarter play? Both are carving out niches with strong therapy launches, rising sales, and acquisitions fueling momentum. Full comparison here 👉 https://www.zacks.com/stock/news/2755750/crmd-vs-mirm-which-specialized-biotech-stock-is-the-better-pick?cid=sm-stocktwits-2-2755750-teaser-13677&ADID=SYND_STOCKTWITS_TWEET_2_2755750_TEASER_13677
0 · Reply
davirom
davirom Sep. 19 at 2:27 AM
$MIRM shall we go for a 92$ buyout? I am revising my selling price ⬆️ month after month 😅
1 · Reply
anachartanalyst
anachartanalyst Sep. 12 at 4:02 PM
$MIRM https://anachart.com/wp-content/uploads/ana_temp/1757692918_soc-img.jpg
0 · Reply
Engrdon
Engrdon Sep. 12 at 2:37 PM
$MIRM So JP Morgan bumped up the TP to $77.00. It seems like they are about 1/3 the way to home. 😁 MIRM’s got proven products that are growing fast, a pipeline that’s partially de-risked in areas where people really need it, and a company with a proven track record that could make billions of dollars, AND they must look great to big Pharma. I just wish I’d bought more…
1 · Reply
JarvisFlow
JarvisFlow Sep. 12 at 11:30 AM
JP Morgan updates rating for Mirum Pharmaceuticals ( $MIRM ) to Overweight, target set at 53 → 77.
0 · Reply
Latest News on MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 10, 2025, 6:45 PM EDT - 26 days ago

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals, Inc. (MIRM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 8, 2025, 11:13 AM EDT - 4 weeks ago

Mirum Pharmaceuticals, Inc. (MIRM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Mirum Pharmaceuticals Announces Enrollment Completion in the Phase 2b VISTAS Study

Sep 8, 2025, 8:00 AM EDT - 4 weeks ago

Mirum Pharmaceuticals Announces Enrollment Completion in the Phase 2b VISTAS Study

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

Aug 27, 2025, 4:02 PM EDT - 5 weeks ago

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

Mirum Pharmaceuticals: Q2 Results Continue To Show Positive Momentum

Aug 11, 2025, 9:48 AM EDT - 2 months ago

Mirum Pharmaceuticals: Q2 Results Continue To Show Positive Momentum

Mirum Pharmaceuticals, Inc. (MIRM) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 9:09 PM EDT - 2 months ago

Mirum Pharmaceuticals, Inc. (MIRM) Q2 2025 Earnings Call Transcript

Mirum Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 6, 2025, 4:01 PM EDT - 2 months ago

Mirum Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Mirum Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025

Jul 30, 2025, 4:01 PM EDT - 2 months ago

Mirum Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025

Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer

May 19, 2025, 8:30 AM EDT - 5 months ago

Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer

Volixibat Data from Mirum's VANTAGE PBC Study Showcased at EASL

May 9, 2025, 8:30 AM EDT - 5 months ago

Volixibat Data from Mirum's VANTAGE PBC Study Showcased at EASL

Mirum Pharmaceuticals, Inc. (MIRM) Q1 2025 Earnings Call Transcript

May 7, 2025, 9:17 PM EDT - 5 months ago

Mirum Pharmaceuticals, Inc. (MIRM) Q1 2025 Earnings Call Transcript

Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May 7, 2025, 4:01 PM EDT - 5 months ago

Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

Mirum Pharmaceuticals: A Respectable Liver, Rare Disease Franchise With Pipeline Opportunities

May 4, 2025, 6:45 PM EDT - 5 months ago

Mirum Pharmaceuticals: A Respectable Liver, Rare Disease Franchise With Pipeline Opportunities

Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025

Apr 30, 2025, 8:30 AM EDT - 5 months ago

Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025

Mirum Pharmaceuticals to Present Data at Upcoming Medical Congresses

Apr 28, 2025, 8:30 AM EDT - 5 months ago

Mirum Pharmaceuticals to Present Data at Upcoming Medical Congresses

Mirum's LIVMARLI Now FDA Approved in Tablet Formulation

Apr 14, 2025, 8:30 AM EDT - 6 months ago

Mirum's LIVMARLI Now FDA Approved in Tablet Formulation

LIVMARLI Now Approved in Japan for ALGS and PFIC

Mar 27, 2025, 8:30 AM EDT - 6 months ago

LIVMARLI Now Approved in Japan for ALGS and PFIC

Mirum Pharmaceuticals: Set Fair For Share Price Momentum - Reversing My Sell Call

Mar 24, 2025, 5:17 PM EDT - 7 months ago

Mirum Pharmaceuticals: Set Fair For Share Price Momentum - Reversing My Sell Call

Mirum Pharmaceuticals, Inc. (MIRM) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 7:10 AM EST - 7 months ago

Mirum Pharmaceuticals, Inc. (MIRM) Q4 2024 Earnings Call Transcript

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

Feb 26, 2025, 4:01 PM EST - 7 months ago

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

Mirum's CTEXLI™ (chenodiol) Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis (CTX)

Feb 24, 2025, 8:30 AM EST - 8 months ago

Mirum's CTEXLI™ (chenodiol) Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis (CTX)

US FDA approves Mirum Pharma's genetic disorder drug

Feb 21, 2025, 12:01 PM EST - 8 months ago

US FDA approves Mirum Pharma's genetic disorder drug

Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call on February 26, 2025

Feb 19, 2025, 4:04 PM EST - 8 months ago

Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call on February 26, 2025

Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates

Jan 13, 2025, 8:30 AM EST - 9 months ago

Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates

Top 5 Commercial Biotech Buyout Candidates: Mirum Pharmaceuticals (No. 3)

Jan 8, 2025, 11:05 AM EST - 9 months ago

Top 5 Commercial Biotech Buyout Candidates: Mirum Pharmaceuticals (No. 3)

Mirum Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 4:04 PM EST - 9 months ago

Mirum Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Mirum Pharma: Buy At Dips For Volixibat Potential

Dec 25, 2024, 10:00 AM EST - 10 months ago

Mirum Pharma: Buy At Dips For Volixibat Potential

Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD's The Liver Meeting

Nov 14, 2024, 8:00 AM EST - 11 months ago

Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD's The Liver Meeting

Mirum Pharmaceuticals, Inc. (MIRM) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 1:51 PM EST - 11 months ago

Mirum Pharmaceuticals, Inc. (MIRM) Q3 2024 Earnings Call Transcript

Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 12, 2024, 8:00 AM EST - 11 months ago

Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

Nov 4, 2024, 4:30 PM EST - 1 year ago

Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting

Oct 31, 2024, 8:30 AM EDT - 1 year ago

Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting

Volixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary Cholangitis

Oct 10, 2024, 8:30 AM EDT - 1 year ago

Volixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary Cholangitis

Mirum Pharmaceuticals, Inc. (MIRM) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 9:10 PM EDT - 1 year ago

Mirum Pharmaceuticals, Inc. (MIRM) Q2 2024 Earnings Call Transcript

Mirum Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 7, 2024, 4:01 PM EDT - 1 year ago

Mirum Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Mirum Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 7, 2024

Jul 31, 2024, 4:30 PM EDT - 1 year ago

Mirum Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 7, 2024

Mirum's LIVMARLI Now Approved for PFIC in Patients 12 Months and Older

Jul 25, 2024, 8:30 AM EDT - 1 year ago

Mirum's LIVMARLI Now Approved for PFIC in Patients 12 Months and Older

Bullish On Mirum Pharmaceuticals: Enhanced Portfolio With Strategic Acquisition

Jul 17, 2024, 3:48 AM EDT - 1 year ago

Bullish On Mirum Pharmaceuticals: Enhanced Portfolio With Strategic Acquisition

Mirum Pharmaceuticals' LIVMARLI Approved in the European Union for Patients with PFIC

Jul 8, 2024, 8:30 AM EDT - 1 year ago

Mirum Pharmaceuticals' LIVMARLI Approved in the European Union for Patients with PFIC

Mirum Submits New Drug Application to FDA for Chenodiol for the Treatment of CTX

Jun 28, 2024, 8:30 AM EDT - 1 year ago

Mirum Submits New Drug Application to FDA for Chenodiol for the Treatment of CTX

3 Biotech Stocks For The Second Half Of 2024

Jun 27, 2024, 4:48 PM EDT - 1 year ago

3 Biotech Stocks For The Second Half Of 2024

ALT NTLA

Mirum Pharmaceuticals Highlights Encouraging Data For Rare Liver Disease Therapy From Two Mid-Stage Studies

Jun 17, 2024, 10:53 AM EDT - 1 year ago

Mirum Pharmaceuticals Highlights Encouraging Data For Rare Liver Disease Therapy From Two Mid-Stage Studies

Mirum's Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies

Jun 17, 2024, 8:00 AM EDT - 1 year ago

Mirum's Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies

Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024

Jun 16, 2024, 5:00 PM EDT - 1 year ago

Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024

Mirum Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

Jun 5, 2024, 4:05 PM EDT - 1 year ago

Mirum Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older

May 31, 2024, 8:30 AM EDT - 1 year ago

Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older

Long-Term Data from Mirum's LIVMARLI Studies in ALGS and PFIC to be Presented at EASL Congress

May 29, 2024, 8:30 AM EDT - 1 year ago

Long-Term Data from Mirum's LIVMARLI Studies in ALGS and PFIC to be Presented at EASL Congress

Mirum Pharmaceuticals' LIVMARLI Data Showcased at ESPGHAN Annual Meeting

May 18, 2024, 7:00 AM EDT - 1 year ago

Mirum Pharmaceuticals' LIVMARLI Data Showcased at ESPGHAN Annual Meeting

Mirum Pharmaceuticals, Inc. (MIRM) Q1 2024 Earnings Call Transcript

May 11, 2024, 2:25 PM EDT - 1 year ago

Mirum Pharmaceuticals, Inc. (MIRM) Q1 2024 Earnings Call Transcript

Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

May 8, 2024, 4:02 PM EDT - 1 year ago

Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

MomentumLurker
MomentumLurker Oct. 5 at 11:57 AM
$MIRM Healthcare technology growth. Testing resistance level. Volume expansion needed for continuation. Sector momentum.
0 · Reply
xbibackto65s
xbibackto65s Sep. 26 at 3:21 PM
$MIRM adding
1 · Reply
IN0V8
IN0V8 Sep. 24 at 2:26 PM
$MIRM Buy TD Cowen initiates coverage with buy rating; PT $95
0 · Reply
notreload_ai
notreload_ai Sep. 24 at 12:06 PM
TD Cowen started coverage of $MIRM with a Buy rating and a $95 price target. The company has three successful products for rare liver diseases and is developing volixibat (also known as SHP626) for pruritus.
0 · Reply
ZacksResearch
ZacksResearch Sep. 23 at 2:49 PM
$CRMD or $MIRM — Which biotech stock is the better bet? CorMedix’s DefenCath delivered $78.8M in 2025 H1 sales, propelling a full-year revenue guidance boost, while $MIRM’s Livmarli sales soared 79.1% YoY in H1 2025. Yet, CRMD’s Zacks Rank #1 (Strong Buy) and strategic Melinta acquisition give it a significant edge. Find out why CRMD is the stronger pick 👉 https://www.zacks.com/stock/news/2755750/crmd-vs-mirm-which-specialized-biotech-stock-is-the-better-pick?cid=sm-stocktwits-2-2755750-body-13685&ADID=SYND_STOCKTWITS_TWEET_2_2755750_BODY_13685
0 · Reply
ZacksResearch
ZacksResearch Sep. 23 at 1:49 PM
$CRMD vs. $MIRM — which biotech is the smarter play? Both are carving out niches with strong therapy launches, rising sales, and acquisitions fueling momentum. Full comparison here 👉 https://www.zacks.com/stock/news/2755750/crmd-vs-mirm-which-specialized-biotech-stock-is-the-better-pick?cid=sm-stocktwits-2-2755750-teaser-13677&ADID=SYND_STOCKTWITS_TWEET_2_2755750_TEASER_13677
0 · Reply
davirom
davirom Sep. 19 at 2:27 AM
$MIRM shall we go for a 92$ buyout? I am revising my selling price ⬆️ month after month 😅
1 · Reply
anachartanalyst
anachartanalyst Sep. 12 at 4:02 PM
$MIRM https://anachart.com/wp-content/uploads/ana_temp/1757692918_soc-img.jpg
0 · Reply
Engrdon
Engrdon Sep. 12 at 2:37 PM
$MIRM So JP Morgan bumped up the TP to $77.00. It seems like they are about 1/3 the way to home. 😁 MIRM’s got proven products that are growing fast, a pipeline that’s partially de-risked in areas where people really need it, and a company with a proven track record that could make billions of dollars, AND they must look great to big Pharma. I just wish I’d bought more…
1 · Reply
JarvisFlow
JarvisFlow Sep. 12 at 11:30 AM
JP Morgan updates rating for Mirum Pharmaceuticals ( $MIRM ) to Overweight, target set at 53 → 77.
0 · Reply
chrssyngrg978
chrssyngrg978 Sep. 12 at 10:58 AM
$MIRM Mirum Pharmaceuticals price target raised by $24 at JPMorgan
1 · Reply
joaneegell
joaneegell Sep. 11 at 3:44 PM
$MIRM OK - after a couple months and a nice 30% climb I guess I'm out for a while. This looks like it's drifting back down a bit.
1 · Reply
LMXPERTEN
LMXPERTEN Sep. 10 at 8:26 PM
$MIRM down on no volume
0 · Reply
joaneegell
joaneegell Sep. 9 at 1:24 PM
$MIRM One of the only bios I'm in that isn't a complete piece of shit.
0 · Reply
DrGonzo69
DrGonzo69 Sep. 8 at 2:02 PM
$MIRM So glad I never sold.
0 · Reply
Ellethegirl
Ellethegirl Sep. 5 at 11:00 PM
$MIRM happy dance for all you have done!! Well run studies, asking the right questions and using good methodology
0 · Reply
davirom
davirom Sep. 5 at 2:17 PM
$MIRM Maybe I am wrong (hopefully not), but this stock reminds me of $CBAY. 1) Almost the entire capital was held by institutional investors. 2) Had a crazy run from 12 to 25. 3) Then it stalled for a while, until the buyout at 32.
1 · Reply
PsiXPsi
PsiXPsi Sep. 5 at 12:48 PM
$MIRM Feels like we’ve stalled at this point. May need any update to move it up more.
0 · Reply
LMXPERTEN
LMXPERTEN Aug. 28 at 7:55 PM
$BBIO told you. $MIRM
0 · Reply
kiwitc2000
kiwitc2000 Aug. 27 at 2:33 PM
$MIRM Got in right after earnings, and every morning I marvel at how much higher it goes. Beautiful month, beautiful chart.
0 · Reply
LMXPERTEN
LMXPERTEN Aug. 26 at 4:49 PM
$MIRM Hello WORLD 🌍 Another ATH!!! ‼️ 🚨
0 · Reply
Alpha_Ascendant
Alpha_Ascendant Aug. 25 at 12:45 PM
Sustained climb to $71 last week. This stock looks to be in a new phase of accumulation. Well above all resistance lines. So focused on $PGEN lately, I haven't been following $MIRM developments. Has anyone seen any recent news flow? https://seekingalpha.com/article/4781651-mirum-pharmaceuticals-stock-respectable-liver-and-rare-disease-franchise-with-pipeline-opportunities
1 · Reply